News Image

Ligand Reports Fourth Quarter and Full Year 2024 Financial Results

Provided By GlobeNewswire

Last update: Feb 27, 2025

Robust financial performance driven by full year 2024 royalty revenue growth of 28%

Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share1 of $6.00-$6.25

Read more at globenewswire.com

LIGAND PHARMACEUTICALS

NASDAQ:LGND (4/22/2025, 5:25:00 PM)

After market: 106.47 0 (0%)

106.47

+1.66 (+1.58%)



Find more stocks in the Stock Screener

Follow ChartMill for more